Homocysteine Is Associated With Future Venous Thromboembolism in 2 Prospective Cohorts of Women

Arterioscler Thromb Vasc Biol. 2021 Jul;41(7):2215-2224. doi: 10.1161/ATVBAHA.121.316397. Epub 2021 May 27.

Aaron W Aday^{1

2}, Edward K Duran^{1

3}, Martin Van Denburgh¹, Eunjung Kim¹, William G Christen¹, JoAnn E Manson¹, Paul M Ridker⁴, Aruna D Pradhan⁵

¹ Division of Preventive Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (A.W.A., E.K.D., M.V.D., E.K., W.G.C., J.E.M., P.M.R., A.D.P.).
² Now with Vanderbilt Translational and Clinical Cardiovascular Research Center, Division of Cardiovascular Medicine, Vanderbilt University Medical Center, Nashville, TN (A.W.A.).
³ Now with Cardiovascular Division, University of Minnesota, Minneapolis (E.K.D.).
⁴ Division of Cardiovascular Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (P.M.R.).
⁵ Division of Cardiovascular Medicine, VA Boston Medical Center, Boston, MA (A.D.P.).

Abstract

[Figure: see text].

Trial registration: ClinicalTrials.gov NCT00000541 NCT00000479.

Keywords: biomarker; homocysteine; plasma; pulmonary embolism; venous thromboembolism.